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Background: Resistance of breast cancer cells to the available chemotherapeutics is a major obstacle to successful
treatment. Recent studies have shown that magnetic nanoparticles might have significant application in different
medical fields including cancer treatment. The goal of this study is to verify the ability of magnetic nanoparticles to
sensitize cancer cells to the clinically available chemotherapy.
Methods: The role of iron oxide nanoparticles, static magnetic field, or a combination in the enhancement of the
apoptotic potential of doxorubicin against the resistant breast cancer cells, MCF-7 was evaluated using the MTT
assay and the propidium iodide method.
Results: In the present study, results revealed that pre-incubation of MCF-7 cells with iron oxide nanoparticles
before the addition of doxorubicin did not enhance doxorubicin-induced growth inhibition. Pre-incubation of
MCF-7 cells with iron oxide nanoparticles followed by a static magnetic field exposure significantly (P< 0.05) increased
doxorubicin-induced cytotoxicity. Sensitization with pre-exposure to the magnetic field was dose-dependent where the
highest cytotoxicity was seen at 1 tesla. Further experiments revealed that the anti-proliferative effect of this treatment
procedure is due to induction of apoptotic cell death.
Conclusions: These results might point to the importance of combining magnetic nanoparticles with a static magnetic
field in treatment of doxorubicin-refractory breast cancer cells.
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Breast cancer is the most commonly diagnosed cancer
among females world-wide. There are currently more than
one million women worldwide fighting breast cancer,
accounting for more than one-fifth of the global burden of
cancers. In more developed and less developed countries,
incidence rates vary widely, ranging from age-standardized
rate 20.7 in Uganda to 90.7 in the USA per 100,000 [1]. In
Europe, 421,000 cases of breast cancer among women
were estimated in 2008 [2] and it is estimated that 184,450
new cases of invasive stages were diagnosed in the USA in
2008 and 230,480 in 2011 [3]. In Jordan, according to the
Jordan Cancer Registry’s 2008 Cancer Incidence in Jordan
Report, breast cancer constituted 35.3% of all cancer cases
in women [4].* Correspondence: kjarrah@just.edu.jo
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reproduction in any medium, provided the orResistance of breast cancer cells to available chemothera-
peutics is a major obstacle to successful treatment.
Although the cure rate from excision of the primary tumor
is high, once the disease spreads to distant sites it is usually
incurable by current systemic therapies, such as chemo-
therapy, radiotherapy, hormonal therapy and immuno-
therapy. The development of a novel approach for early
detection, treatment and overcoming resistance of
cancers is potentially required [5].
Anthracyclines are some of the most commonly used
anticancer agents. The first generation of anthracyclines
were isolated from the pigment-producing Streptomyces
peucetius and were named doxorubicin and daunorubicin
[6]. Doxorubicin (Adriamycin), a powerful drug in the
fight against cancer, joined the oncologic practice in the
late 1960s [7]. It exerts antitumor activity through its in-
hibition of topoisomerase II, and thus prevents chain
unfolding and separation in DNA replication as well asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Representative micrograph for Fe2O3 nanoparticles.
(The scale bar is 50 nm).
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http://www.wjso.com/content/10/1/62DNA repair. This ultimately leads to cell death, called
apoptosis. Other mechanisms that might be involved are
intercalating into DNA, resulting in inhibition of DNA
synthesis and function, and formation of cytotoxic oxygen
free radicals that results in single- and double-stranded
DNA breaks with subsequent inhibition of DNA synthesis
and function.
Iron oxide nanoparticles have been employed in many
biomedical applications due to their attractive properties,
such as stability over time, biocompatibility and sensitivity
to a magnetic field. Furthermore, their capability in many
potential applications in biology and medicine has been
explored, such as a contrast agent in magnetic resonance
imaging (MRI) [8-12], a carrier in drug delivery [13-17],
and as heating agents in the presence of alternating mag-
netic fields. This property can be very efficient in killing
cancer cells through hyperthermia since these magnetic
particles can be guided to the tumor by the external mag-
netic field gradient [18-23]. Furthermore, recent study has
shown that the application of the static magnetic field in
the presence of these particles can reduce cell viability,
apoptosis and cell cycle aberrations [24].
In the present study, we hypothesized that magnetic
nanoparticles might have anticancer activity or are able




Human breast cancer cell line MCF-7 was generously pro-
vided by Dr. Rick F. Thorne, from the Newcastle University,
NSW, Australia, and cultured in DMEM containing 10%
FCS (Bio Whittaker, Verviers, Belgium).
Chemical reagents
Doxorubicin, purchased from Sigma-Aldrich (St. Louis,
MO, USA),was dissolved in dimethyl sulfoxide (DMSO)
and made up in a stock solution of 1 mM. Iron oxide
nanoparticles coated by PVP (polyvinyl pyrorolidone),
Propidium Iodide and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased
from Sigma Aldrich (Sigma-Aldrich).
Preparation of the Fe2O3 nanoparticles
FeCl36H2O (Sigma Aldrich, >99%) and glycine (Sigma
Aldrich, 99%) were mixed to create a solution of 0.1 M
Fe3+, 0.2 M glycine with a total volume of 50 mL. The
solution was then transferred to a Teflon-lined stainless
steel vessel. The vessel was tightly sealed and heated to
150°C for 10 hours and slowly cooled to room
temperature. The pH of the solution was controlled be-
fore and after the hydrothermal process. The precipi-
tate powder was washed repeatedly with deionized
water as well as absolute ethanol and sonicated for 5minutes prior to filtering and drying in a vacuum for
10 hours. The morphology and the microstructure of
the powder were characterized using X-ray diffraction
(XRD) and scanning electron microscope (SEM). The
average size of the spherical-shaped nanoparticles was
found to be about 50 nm. A representative micrograph
of the nanoparticles is shown in Figure 1 (the scale bar
is 50 nm).Cell viability assays
The acute cytotoxic effect of doxorubicin and drug com-
binations on MCF-7 cells was determined using MTT
assays as described previously [25]. Briefly, cells were
seeded at 5,000/well onto flat-bottomed 96-well culture
plates and allowed to grow for 24 hours before the
desired treatment. Cells were then labeled with MTT from
the Vybrant MTT Cell Proliferation Assay Kit (Molecular
Probes, Eugene, OR, USA) according to the manufac-
turer’s instruction and the resulting formazan was solubi-
lized with DMSO. Absorbance was read in a microplate
reader at 540 nm.Apoptosis
Quantitation of apoptotic cells by measurement of sub-G1
DNA content using the PI method was carried out as
described elsewhere [26]. In brief, MCF-7 cells were
adhered overnight in a 24-well plate and incubated with
different treatment combinations. Floating and adherent
cells were then harvested and incubated overnight at 4°C
in the dark with 750 μl of a hypotonic buffer (50 μg/mL PI
in 0.1% sodium citrate plus 0.1% Triton X-100; Sigma)
before flow cytometric analysis using a FACScan flow
cytometer (Becton Dickinson, San Jose, CA, USA).
Figure 3 Effect of SMF on doxorubicin-induced cell cytotoxicity.
Cells were exposed to different strengths of SMF before being
incubated with doxorubicin at 1 μM or with iron oxide nanoparticles
or both for 72 hours and then analyzed for cell growth using MTT
assay. Control groups were treated with DMSO alone. Each value
represents the mean ± SE of three independent experiments
performed with quadruplicate culture.
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Data are expressed as mean ± SE. The statistical signifi-
cance of intergroup differences in normally distributed
continuous variables was determined using Student’s
t-test. P-values ≤ 0.05 were considered statistically sig-
nificant. P-values ≤ 0.05 and ≤ 0.001 are indicated by *
and **, respectively.
Results and discussion
In the present study, we evaluated the potential of spherical
iron oxide nanoparticles (Fe2O3) to sensitize MCF-7 breast
cancer cells to doxorubicin-induced cytotoxicity. MCF-7
cells were pre-incubated with or without Fe2O3 (at
0.5 mM) for 16 hours before the addition of doxorubicin
at 1 μM for another 72 hours. As shown in Figure 2,
pre-incubation with Fe2O3 did not induce cytotxic effect
against MCF-7 cells and did not sensitize MCF-7 cells to
doxorubicin-induced cell growth inhibition. Unlike pre-
vious reports [24], these results showed that iron oxide
nanoparticles might not be the predominant source of
the cytotoxicity.
Previous studies have shown that nanoparticles hold
promise for a variety of biomedical applications due to
their properties of Visualization under magnetic resonance
imaging (MRI), heating with radio frequency and move-
ment in an external magnetic field. Magnetic guidance is
one of the strategies for the accumulation of nanoparticles
and drugs in an affected area. To study the effect of static
magnetic field (SMF) on cytotoxicity induced up on treat-
ment with a combination of doxorubicin and Fe2O3, differ-
ent strengths of SMF were used. Results in Figure 3 show
that pre-exposure to SMF at different strengths did not
sensitize cancer cells when treated with doxorubicin alone.Figure 2 Doxorubicin effect on growth of MCF-7 breast
carcinoma cells. Cells were incubated with doxorubicin at 1 μM or
with iron oxide nanoparticles or both for 72 hours and then
analyzed for cell growth using MTT assay. Control groups were
treated with DMSO alone. Each value represents the mean ± SE of
three independent experiments performed with quadruplicate
culture.Moreover, sensitization of cancer cells to doxorubicin by
SMF was dose-dependent and seemed to be Fe2O3-
dependent.
We next studied if the growth inhibition occurred by
pre-exposure to SMF was due to induction of cellular
death. MCF-7 cells were pre-incubated with Fe2O3 for
16 hours before they were exposed to SMF at 1 tesla
and followed by the addition of doxorubicin for another
72 hours. As shown in Figure 4, cells pre-incubated with
Fe2O3 and exposed to the SMF before the treatment with
doxorubicin experienced a significant (P< 0.05) increaseFigure 4 Effect of SMF or iron oxide nanoparticles on
doxorubicin-induced cell apoptosis. Cells were exposed to SMF at
1 tesla before being incubated with doxorubicin at 1 μM or with
iron oxide nanoparticles or both for 72 hours and then analyzed for
cell apoptosis using the propidium iodide method. Results represent
the mean ± SE of three independent experiments.
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treatment might sensitize cancer cells to doxorubicin-
induced apoptotic cell death.
Several cellular compartments, such as lipids, carbohy-
drates and nucleic acids, might be damaged by increased
levels of reactive oxygen species (ROS) in that increased
levels of ROS might induce irreversible damage to DNA
[27,28]. Cell death inducers, such as chemotherapy and
ionizing radiotherapy, have been shown to induce their
cytotoxicity through ROS generation [29-32]. Our results
showed that treatment with Fe2O3 particles alone are un-
able to inhibit cancer cell growth largely due to the inability
to generate ROS (data not shown). Other studies showed
that in the presence of a SMF, FeCl2 induces DNA damage
in an ROS-dependent manner indicating that SMF, some-
how, has a role in activating ROS generation from FeCl2
[33-35]. This might be not the situation in the present
study since FeCl2 has been removed by nanoparticle
washing. Consistent with our studies, it has been shown
that SMF induces apoptotic cell death, particularly in
human transformed cells and in rat tendon fibroblasts
cell cultures [36-39]. Furthermore, results in the present
study revealed that the SMF without the addition of the
ROS generator, Fe2O3, or the ROS inducer, doxorubicin,
is unable to induce cancer cell growth inhibition. This
was consistent with previous studies showing that SMF
did not enhance the rate of apoptotic cells without the
addition of hydrogen peroxide [40].
The apoptotic potential of SMF might be due to the
ability of SMF to induce marked alteration in cellular
shape [41]. In addition to the oxidative stress induced by
Fe2O3, this effect might lead to physical stress that will
modulate the intracellular levels of calcium. Alteration in
the intracellular levels of calcium has been shown to in-
duce a response called unfolded protein response (UPR).
The later occurs due to increased accumulation of mis-
or malfolded proteins. Persistence of UPR signaling in
presence of doxorubicin and Fe2O3, the cell will die by
induction of the endoplasmic reticulum (ER) stress [42].
Another proposed mechanism for cell death is that
SMF might inhibit DNA repair procedures [43,44]. Thus
DNA damage induced by topoisomerase I inhibitor,
doxorubicin, will not be repaired and cells will commit
suicide, probably by induction of one or more of the ER
stress signaling arms [42].
Conclusions
Collectively, these results indicate that intra-tumor im-
plantation of Fe2O3 followed by exposure to a SMF and
doxorubicin might provide a promising approach in the
treatment of patients with breast cancer and for those
being refractory to doxorubicin. This is strongly supported
by previous findings, indicating that iron oxide particles
have long blood retention rates and are biodegradable [5].Abbreviations
DMSO: Dimethyl sulfoxide; DMEM: Dulbecco’s modified Eagle’s medium;
ER: Endoplamic reticulum; FCS: FACScan flow cytometer; MRI: Magnetic
resonance imaging; PVP: Polyvinyl pyrorolidone; ROS: Reactive oxygen
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magnetic field; UPR: Unfolded protein response; XRD: X-ray diffraction.
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